MARKET

ADRO

ADRO

Aduro Biotech
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.600
+0.080
+3.17%
Opening 13:37 03/31 EDT
OPEN
2.510
PREV CLOSE
2.520
HIGH
2.796
LOW
2.470
VOLUME
193.81K
TURNOVER
--
52 WEEK HIGH
4.590
52 WEEK LOW
0.9011
MARKET CAP
209.98M
P/E (TTM)
-2.5289
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ADRO and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ADRO stock price target is 7.33 with a high estimate of 10.00 and a low estimate of 4.000.

EPS

ADRO News

More
  • Aduro Biotech (ADRO) Gains As Market Dips: What You Should Know
  • Zacks · 03/23 22:50
  • Aduro: Float Like A Butterfly, Sting Like A Bee
  • Seeking Alpha - Article · 03/18 16:56
  • Is Aduro Biotech (ADRO) Outperforming Other Medical Stocks This Year?
  • Zacks · 03/16 16:30
  • Aduro's (ADRO) Earnings & Revenues Miss Estimates in Q4
  • Zacks · 03/11 19:20

Industry

Biotechnology & Medical Research
-1.71%
Pharmaceuticals & Medical Research
-0.56%

Hot Stocks

Symbol
Price
%Change

About ADRO

Aduro Biotech, Inc. is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company's product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies. Its LADD technology platform is being developed as a treatment for multiple indications, including mesothelioma, ovarian, gastric, lung and prostate cancers. Its LADD product candidate is CRS-207, which is being developed as a treatment for multiple indications, including mesothelioma, ovarian and gastric cancers. ADU-214 and ADU-741 are product candidates in development for lung and prostate cancers, respectively.
More

Webull offers kinds of Aduro BioTech Inc stock information, including NASDAQ:ADRO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADRO stock news, and many more online research tools to help you make informed decisions.